https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

Abemaciclib significantly enhances overall survival in high-risk HR+, HER2- early breast cancer, establishing a new standard of care.

administrator

Related Articles